CPIX · NASDAQ
Cumberland Pharmaceuticals Inc.
$4.53 -3.96 (-46.64%)
Company overview
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for treating acetaminophen poisoning; Caldolor, an injection for treating pain and fever; Kristalose, a prescription laxative oral solution for treating chronic and acute constipation; Omeclamox-Pak for treating Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for treating certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NASDAQ
- Market cap
- $67.9M
- Employees
- 91
- Headquarters
- Nashville, TN
- Website
- cumberlandpharma.com
- CEO
- A. J. Kazimi
- Listed
- August 11, 2009
- P/E
- -9.30
- Dividend yield
- 19.31%
Company financials
- Revenue
- $41.9M
- Gross profit
- $34.8M
- Operating income
- -$7.2M
- EBITDA
- -$1.9M
- Net income
- -$7.2M
- EPS
- -$0.49
- Total assets
- $71M
- Total debt
- $10.1M
- Gross margin
- 82.89%
- Net margin
- -17.24%
- Earnings yield
- -10.75%
Showing FY 2025
CPIX
1D
NASDAQ
O8.46H8.76L8.33C8.49+0.01 (+0.12%)Vol44.31K